Pharmacotherapy for Opioid Dependence

Treating Alcohol and Drug Abuse: An Evidence Based Review

Volumn , Issue , 2004, Pages 465-531

  Johansson, Björn Axel ^a  

^a NONE   (Sweden)

Author keywords

Agonists; Antagonists; Antidepressants; Opioid dependence; Pharmacotherapy

Indexed keywords

EID: 20044380315     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527601465.ch8     Document Type: Chapter

References (77)

1. Banys P, Tusel DJ, Sees KL, Reilly PM, Delucchi KL. Low (40 mg) versus high (80 mg) dose methadone in a 180-day heroin detoxification program. J Subst Abuse Treat 1994; 11:225-232.
2. Bickel WK, Stitzer ML, Bigelow GE, Liebson IA, Jasinski DR, Johnson RE. A clinical trial of buprenorphine: comparison with methadone in the detoxification of heroin addicts. Clin Pharmacol Ther 1988; 43:72-78.
3. Caplehorn JRM, Stella M, Dalton YN, Halder F, Petrenas A-M, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. Subst Use Misuse 1996; 31:177-196.
4. Chapleo CB. European Studies. Research & Clinical Forums 1999; 21:29-36.
5. Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B, O'Brien CP. Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 1997; 14:529-534.
6. Curran S, Savage C. Patient response to naltrexone: issues of acceptance, treatment effects, and frequency of administration. NIDA Res Monogr 1976; 9:67-69.
7. Dole VP, Nyswander MA. A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride. JAMA 1965; 193:646-650.
8. Dole VP, Robinson JW, Orraca J, Towns E, Searcy P, Caine E. Methadone treatment of randomly selected criminal addicts. N Engl J Med 1969; 280:1372-1375.
9. Eissenberg T, Bigelow GE, Strain EC, Walsh SL, Brooner RK, Stitzer ML, Johnson RE. Dose-related efficacy of Levomethadyl acetate for treatment of opioid dependence. A randomized clinical trail. JAMA 1997; 277:1945-1951.
10. Farrell M, Ward J, Mattick R, Hall W, Timson GV, des Jarlais D, Gossop M, Strang J. Methadone maintenance treatment in opiate dependence: a review. BMJ 1994; 309:997-1001.
11. Fischer G, Gombas W, Eder H, Jagsch R, Peternel A, Stühlinger G, Pezawas L, Aschauer HN, Kasper S. Buprenorfin versus methadone maintenance for the treatment of opioid dependence. Addiction 1999; 94:1337-1347.
12. Freedman RR, Czertko G. A comparison of thrice weekly LAAM and daily methadone in employed heroin addicts. Drug Alcohol Depend 1981; 8:215-22.
13. Gerra G, Marcato A, Caccavari R, Fontanesi B, Del Signore R, Fertonani G, Avanzini P, Rustichelli P, Passeri M. Clonidine and opiate receptor antagonists in the treatment of heroin addiction. J Subst Abuse Treat 1995; 12:35-41.
14. Glans M, Klawansky S, McAullife W, Chalmers T. Methadone vs l-alphaacetyl- methadol (LAAM) in the treatment of opiate addictions. A meta-analysis of the randomized controlled trails. Am J Addiction 1997; 6:339-349.
15. Gunne LM, Grönbladh L. The Swedish methadone maintenance program: A controlled study. Drug Alcohol Depend 1981; 7:249-256.
16. Hartnoll RL, Mitcheson MC, Battersby A, Brown G, Ellis M, Fleming P, Hedley N. Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 1980; 37:877-884.
17. Higgins ST, Stitzer ML, Bigelow GE, Liebson IA. Contingent methadone delivery: effects on illicit-opiate use. Drug Alcohol Depend 1986; 17:311-22.
18. Hollister LE, Bearman JE, Duster TS, Freedman DX, Gallant DM, Harris LS, Jarvik ME, Jasinski DR, Klett CJ, Kleber H, Hurzeler M, Savage C, Schoof K, Ling W, Haas N, Parwatikar S. Clinical evaluation of naltrexone treatment of opiate-dependent individuals. Report of the national research council committee on clinical evaluation of narcotic antagonists. Arch Gen Psychiatry 1978; 35:335-340.
19. Hurzeler M, Gerwirtz D, Kleber H. Varying clinical contexts for administering naltrexone. NIDA Res Monogr 1976; 9:48-66.
20. Jaffe JH, Senay EC. Methadone and l-methadyl acetate: use in management of narcotic addicts. JAMA 1971; 216:1303-1305.
21. Jaffe JH, Senay EC, Schuster CR, Renault PR, Smith B, Di Menza S. Methadyl acetate vs methadone. A double-blind study in heroin users. JAMA 1972; 222:437-442.
22. Johnson RE, Jaffe JH, Fudala PJ. A controlled trial of buprenorphine treatment for opioid dependence. JAMA 1992; 267:2750-2755.
23. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 1995; 40:17-25.
24. Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 1995; 40:27-35.
25. Johnson RE, Chutuape MA, Strain EC, Walsh SL, Stitzer ML, Bigelow GE. A comparison of levomethadyl acetate, buprenorphine and methadone for opioid dependence. N Engl J Med 2000; 343:1290-1297.
26. Jones HE, Strain EC, Bigelow GE, Walsh SL, Stitzer ML, Eissenberg T, Johnson RE. Induction with levomethadyl acetate: safety and efficacy. Arch Gen Psychiatry 1998; 55:729-736.
27. Karp-Gelernter E, Savage C, McCabe OL. Evaluation of clinic schedules for LAAM and methadone: a controlled study. Int J Addictions 1982; 17:805-813.
28. Kidorf M, Stitzer ML, Brooner RK, Goldberg J. Contingent methadone take-home doses reinforce adjunct therapy attendance of methadone maintenance patients. Drug Alcohol Depend 1994; 36:221-216.
29. Kirchmayer U, Davoli M, Verster A. Naltrexone maintenance treatment for opioid dependence. The Cochrane Database of Systematic Reviews. The Cochrane Library, the Cochrane Collaboration, Vol (2) 1999.
30. Kleber HD, Weissman MM, Rounsaville BJ, Wilber CH, Prusoff BA, Riordan CE. Imipramine as treatment for depression in addicts. Arch Gen Psychiatry 1983; 40:649-653.
31. Kosten TR, Morgan C, Kleber HD. Phase II clinical trials of buprenorphine: detoxification and induction onto naltrexone. NIDA Res Monogr 1992; 121:101-119.
32. Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 1993; 181:358-364.
33. Kosten TR, Rayford BS. Effects of ethnicity on low-dose opiate stabilization. J Subst Abuse Treat 1995; 12:111-116.
34. Ladewig D. Naltrexone - an effective aid in the psychosocial rehabilitation process of former opiate dependent patients. Ther Umsch 1990; 47:247-250.
35. Landabaso MA, Iraurgi I, Jiménez-Lerma JM, Sanz J, Fernádes de Corves B, Araluce K, Calle R, Gutiérrez-Fraile M. TCA randomized trail of adding fluoxetine to a naltrexone treatment programme for heroine addicts. Addiction 1998; 93:739-744.
36. Lerner A, Sigal M, Bacalu A, Schiff R, Burganski I, Gelkopf M. A naltrexone double blind placebo controlled study in Israel. Isr J Psychiatry Relat Sci 1992; 29:36-43.
37. Ling W, Charuvastra C, Kaim SC, Klett CJ. Methadyl acetate and methadone as maintenance treatments for heroin addicts. Arch Gen Psychiatry 1976; 33:709-719.
38. Ling W, Wesson DR, Charuvastra C, Klett CJ. A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 1996; 53:401-407.
39. Ling W, Charuvastra C, Collins JF, Batki S, Brown Jr LS, Kintaudi P, Wesson DR, McNicholas L, Tusel DJ, Malkerneker U, Rener Jr JA, Santos E, Casadonte P, Fye C, Stine S, Wang RIH, Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter randomized clinical trail. Addiction 1998; 93:475-486.
40. Marsch LA. The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 1998; 93:515-532.
41. Mello NK, Mendelson JH, Kuehnle JC, Sellers MS. Operant analysis of human heroin self-administration and the effects of naltrexone. J Pharmacol Exp Ther 1981; 216:45-54.
42. Newman RG, Whitehill WB. Doubleblind comparison of methadone and placebo maintenance treatments of narcotic addicts in Hong Kong. Lancet 1979; 2(8141):2485-2488.
43. NIH Consensus Conference. Effective medical treatment of opiate addiction. JAMA 1998; 280:1936-1943.
44. Nunes EV, Quitkin FM, Donovan SJ, Deliyannides D, Ocepek-Welikson K, Koenig T, Brady R, McGrath PJ, Woody G. Imipramin treatment of opiate-dependent patients with depressive disorders. A placebo-controlled trail. Arch Gen Psychiatry 1998; 55:526-530.
45. O'Connor PG, Oliveto AH, Shi JM, Triffleman EG, Carroll KM, Kosten TR, Rounsaville BJ, Pakes JA, Schottenfeld RS. A randomized trial of buprenorphine maintenance for heroin dependence in primary care clinic for substance users vs a methadone clinic. Am J Med 1998; 105:100-105.
46. O'Connor PG, Fiellin DA. Pharmacologic treatment of heroin-dependent patients. Ann Intern Med 2000; 133:40-54.
47. Oliveto AH, Farren C, Kosten TR. Effect of LAAM dose on opiate use in opioid-dependent patients. A pilot study. Am J Addict 1998; 7:272-282.
48. Osborn E, Grey C, Reznikoff M. Psychosocial adjustment, modality choice and outcome in naltrexone versus methadone treatment. Am J Drug Alcohol Abuse 1986; 12:383-388.
49. Panell J, Charuvastra C, Ouren J. Methadyl acetate vs. methadone: the experience of one hospital. Med J Aust 1977; 2:150-152.
50. Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL. Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 2000; 60:39-50.
51. Perneger TV, Giner F, del Rio M, Mino A. Randomised trial of heroin maintenance programme for addicts who fail in conventional drug treatments. BMJ 1998; 317:13-18.
52. Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger O, Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 2001; 62:97-104.
53. Petrakis I, Carroll KM, Nich C, Gordon L, Kosten T, Rounsaville B. Fluoxetine treatment of depressive disorders in methadone-maintained opioid addicts. Drug Alcohol Depend 1998; 150:221-226.
54. Preston KL, Silverman K, Umbricht A, Dejsens A, Montoya ID, Schuster CR. Improvement in naltrexone treatment compliance with contingency management. Drug Alcohol Depend 1999; 54:127-135.
55. Preston KL, Umbricht A, Epstein DH. Methadone dose increase and abstinence reinforcement for treatment of continued heroin use during methadone maintenance. Arch Gen Psych 2000; 57:359-404.
56. Rawson RA, Glazer M, Callahan EJ, Liberman RP. Naltrexone and behavior therapy for heroin addiction. NIDA Res Monogr 1979; 26-43.
57. Rhoades HM, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998; 88(1):34-39.
58. San L, Pomarol G, Peri JM, Olle JM, Cami J. Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 1991; 86:983-990.
59. Savage C, Karp EG, Curran SF, Hanlon TE, Mc Cabe OL. Methadone/LAAM maintenance: a comparison study. Compr Psych 1976; 17:415-424.
60. Schottenfeld RS, Pakes JR, Oliveto A, Ziedonis D, Kosten TR. Buprenorphine vs methadone maintenance treatment for concurrent opioid dependence and cocaine abuse. Arch Gen Psychiatry 1997; 54:713-720.
61. Schottenfeld RS, Pakes JR, Kosten TR. 1998. Prognostic factors in buprenorphine- versus methadone-maintained patients. J Nerv Ment Dis 1998; 186:35-43.
62. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Barneys P, Hall SM. Methadone maintenance vs 180 day psychosocially enriched detoxification for treatment of opioid dependence. A randomized controlled trail. JAMA 2000; 283:1303-1310.
63. Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginaty Y. The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 1994; 35:935-945.
64. Stitzer ML, Iguchi MY, Felch LJ. Contingent take-home incentive: effects on drug use of methadone maintenance patients. J Consult Clin Psychol 1992; 60:927-934.
65. Strain EC, Stitzer ML, Liebson IA. Dose-response effects of methadone in the treatment of opioid dependence. Ann Intern Med 1993; 119:23-27.
66. Strain EC, Stitzer ML, Liebson IA, Biglow GE. Methadone dose and treatment outcome. Drug Alcohol Depend 1993; 33:105-117.
67. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioiddependent cocaine users. Psychopharmacology 1994; 116:401-406.
68. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 1994; 151:1025-1030.
69. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Outcome after methadone treatment: influence of prior treatment factors and current treatment status. Drug Alcohol Depend 1994; 35:223-230.
70. Strain EC, Stitzer ML, Liebson IA, Bigelow GE. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. J Clin Psychopharmacol 1996; 16:8-67.
71. Strain EC, Bigelow GE, Liebson IA, Stitzer ML. Moderate- vs high-dose methadone in the treatment of opioid dependence. JAMA 1999; 281:1000-1005.
72. Titievsky J, Seco G, Barranco M, Kyle EM. Doxepin as adjunctive therapy for depressed methadone maintenance patients: a double blind study. J Clin Psychiatry 1982; 43:454-456.
73. Valmaña A. Nonmethadone pharmacotherapies in opioid addiction. Current Opinion in Psychiatry 1999; 12:307-310.
74. Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K. A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: implications for prevention of HIV. Int J Addict 1991; 26:1313-1320.
75. Ward J, Hall W, Mattick RP. Role of maintenance treatment in opioid dependence. Lancet 1999; 353:221-226.
76. Woody GE, O'Brien CP, Rickels K. Depression and anxiety in heroin addicts: A placebo-controlled study of doxepin in combination with methadone. Am J Psychiatry 1975; 132:447-450.
77. Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, Robinson JW. A randomized trial of an interim methadone maintenance clinic: see comments. Am J Publ Health 1991; 81:1185-1191.